Companies › Changchun BCHT Biotechnology
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Other, Infectious disease; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DTacP Cell-free diphtheria and tetanus toxoid (three-component) combined vaccine | – | Phase 3 | Prevent Whooping Cough | Jun 2032 |
| Adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine Combination vaccine containing diphtheria toxoid, tetanus toxoid, and two-component acellu | – | Phase 2 | Pertussis (Whooping Cough) | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07894055 | Adsorbed acellular pertussis (two-component) diphtheria-tetanus combined vaccine | Phase 2 | Pertussis (Whooping Cough) | Infectious disease | Aug 2027 |
| NCT07112144 | DTacP | Phase 3 | Prevent Whooping Cough | Other | Jun 2032 |
No annotated target.
–
Bavarian Nordic Sinovac Life Sciences Bharat Biotech International Beijing Zhifei Lvzhu Biopharmaceutical Castle Creek Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.